Clinical study on increased serum thyroxine-binding globulin in cancerous state.
Serum thyroxine-binding globulin (TBG) in 169 patients with various cancers was determined by radioimmunoassay (RIA). Eleven patients showed a high serum TBG level (greater than 35 micrograms/ml). Two of them had been treated with estrogen for prostate cancer. One patient had high serum TBG with serum hepatitis. Another 8 cases had normal liver function and also normal levels serum estrogen. Thus, about 4.7% (8/169) of the cancer patients had high serum TBG and mild hyperthyroxinemia caused by unknown mechanisms. The high TBG level in these patients continued until just before death, or in some cases decreased to normal after removal of cancer tumors by operation. Cancer is occasionally associated with an increase in serum TBG. Although the mechanism is not clear, the increased TBG in the cancerous state in interesting and has significance as a tumor marker.
D000328:Adult; D000368:Aged; D000510:Alpha-Globulins / Q000378:metabolism*; D002272:Carcinoembryonic Antigen / Q000032:analysis; D006063:Chorionic Gonadotropin / Q000097:blood; D004967:Estrogens / Q000097:blood; D005260:Female; D006801:Humans; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood*; D011228:Prealbumin / Q000378:metabolism; D013960:Thyroid Function Tests; D013975:Thyroxine-Binding Proteins / Q000378:metabolism*
D000510:Alpha-Globulins; D002272:Carcinoembryonic Antigen; D006063:Chorionic Gonadotropin; D004967:Estrogens; D011228:Prealbumin; D013975:Thyroxine-Binding Proteins